Pancreatic Cancer Research

ResearcherMiyazaki Prefectural HospitalActive in the last 2 years

Shuji Arita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-3795-8787; OpenAlex author ID A5005510045, A5055627370. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers · 2025: 6 papers · 2026: 6 papers

Papers 16

  1. Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folini… Co-author DOI 10.1002/ijc.70072↗
  2. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  3. Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluor… Co-author DOI 10.1177/17588359261442386↗
  4. Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic ac… Co-author DOI 10.1186/s12885-026-16237-2↗
  5. Dynamic analysis of C-reactive protein/albumin ratio in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-8417823/v1↗
  6. Pneumocystis Pneumonia in a Patient Receiving Nab-paclitaxel Plus Gemcitabine for Unresectable Pancreatic Cancer. Last author DOI 10.2169/internalmedicine.5315-25↗
  7. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Co-author DOI 10.1016/j.esmogo.2025.100150↗
  8. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  9. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Co-author DOI 10.1177/17588359251320768↗
  10. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… Co-author DOI 10.1177/17588359251393156↗
  11. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  12. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  13. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  14. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  15. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  16. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 14 shared papers, 2023–2026 · strength 2.38
  2. Kenji Mitsugi · 14 shared papers, 2023–2026 · strength 2.38
  3. Shiho Arima · 14 shared papers, 2023–2026 · strength 2.38
  4. Futa Koga · 14 shared papers, 2023–2026 · strength 2.38
  5. Mototsugu Shimokawa · 14 shared papers, 2023–2026 · strength 2.38
  6. Taiga Otsuka · 14 shared papers, 2023–2026 · strength 2.38
  7. Tsuyoshi Shirakawa · 14 shared papers, 2023–2026 · strength 2.38
  8. Kazuo Nishikawa · 14 shared papers, 2023–2026 · strength 2.38
  9. Hiroki Taguchi · 14 shared papers, 2023–2026 · strength 2.38
  10. Yasunori Kawaguchi · 14 shared papers, 2023–2026 · strength 2.38
  11. Taro Shibuki · 10 shared papers, 2023–2026 · strength 1.58
  12. Keisuke Miwa · 10 shared papers, 2023–2026 · strength 1.58
  13. Azusa Komori · 10 shared papers, 2023–2026 · strength 1.58
  14. Yasushi Ide · 6 shared papers, 2024–2026 · strength 1.10
  15. Tomonori Araki · 4 shared papers, 2025–2026 · strength 0.73
  16. Akio Ido · 4 shared papers, 2023–2026 · strength 0.60
  17. Yoshinobu Okabe · 4 shared papers, 2023–2024 · strength 0.54
  18. Masaru Fukahori · 3 shared papers, 2024–2025 · strength 0.47
  19. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  20. Akihisa Takano · 1 shared paper, 2026 · strength 0.32
  21. Norio Ureshino · 2 shared papers, 2024–2025 · strength 0.30
  22. Atsuko Kakihara · 1 shared paper, 2026 · strength 0.20
  23. Wataru Yoshioka · 1 shared paper, 2026 · strength 0.20
  24. Akiko Todaka · 1 shared paper, 2025 · strength 0.17
  25. Tomomi Koike · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.